NCT06469853View on ClinicalTrials.gov

Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of MBF-015 in Huntington's Disease Patients

PHASE2CompletedINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

February 1, 2024

Primary Completion Date

December 4, 2024

Study Completion Date

December 4, 2024

Conditions

Huntington Disease

Interventions

DRUG

MBF-015 16 mg oral capsules

MBF-015 oral capsules HDAC inhibitor

Trial Locations (1)

08025

Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau, Barcelona

Sponsors

Lead Sponsor

Medibiofarma S.L.

All Listed Sponsors

lead

Medibiofarma S.L.

INDUSTRY

NCT06469853 - Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of MBF-015 in Huntington's Disease Patients | Biotech Hunter | Biotech Hunter